Against targeted investment of Rs. 3,938 crore, investments worth Rs. 4,024 crores have been made under scheme
A one-time dose of DURVEQTIX has reduced bleeds post-treatment compared to standard of care with a median annualized bleed rate (ABR) of zero bleeds (range 0 to 9.9)
Susvimo is a unique therapeutic approach that provides continuous delivery of medicine to the eye through a refillable implant
Cyclosporine Ophthalmic Nanoemulsion is a preservative-free Nanoemulsion that has been approved in South Korea, Peru and several countries in the Middle East for treatment of dry eye syndrome
Vonoprazan is a potassium-competitive acid blocker (P-CAB) used for the treatment of acid-related disorders
An investigational CYP11A1 Inhibitor, for the treatment of metastatic castration-resistant prostate cancer
PIVOTAL is an open label, randomized, multicenter, Phase III trial evaluating Nidlegy as a neoadjuvant intralesional therapy
Acceptance based on results demonstrated a statistically significant improvement in overall survival versus chemotherapy alone in these patients
Subscribe To Our Newsletter & Stay Updated
